Literature DB >> 9546347

Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

M Baba1, S Nakajo, P H Tu, T Tomita, K Nakaya, V M Lee, J Q Trojanowski, T Iwatsubo.   

Abstract

Lewy bodies (LBs) are hallmark lesions of degenerating neurons in the brains of patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Recently, a point mutation in the gene encoding the presynaptic alpha-synuclein protein was identified in some autosomal-dominantly inherited familial PD pedigrees, and light microscopic studies demonstrated alpha-synuclein immunoreactivity in LBs of sporadic PD and DLB. To characterize alpha-synuclein in LBs, we raised monoclonal antibodies (MAbs) to LBs purified from DLB brains and obtained a MAb specific for alpha-synuclein that intensely labeled LBs. Light and electron microscopic immunocytochemical studies performed with this MAb as well as other antibodies to alpha-and beta-synuclein showed that alpha-synuclein, but not beta-synuclein, is a component of LBs in sporadic PD and DLB. Western blot analyses of highly purified LBs from DLB brains showed that full-length as well as partially truncated and insoluble aggregates of alpha-synuclein are deposited in LBs. Thus, these data strongly implicate alpha-synuclein in the formation of LBs and the selective degeneration of neurons in sporadic PD and DLB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546347      PMCID: PMC1858234     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.

Authors:  P H Weinreb; W Zhen; A W Poon; K A Conway; P T Lansbury
Journal:  Biochemistry       Date:  1996-10-29       Impact factor: 3.162

Review 2.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC.

Authors:  P H Jensen; P Hojrup; H Hager; M S Nielsen; L Jacobsen; O F Olesen; J Gliemann; R Jakes
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

4.  Familial Parkinson's disease. The awakening of alpha-synuclein.

Authors:  M Goedert
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

Review 5.  Neuropathology of Parkinson's disease.

Authors:  L S Forno
Journal:  J Neuropathol Exp Neurol       Date:  1996-03       Impact factor: 3.685

6.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

7.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

8.  Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease.

Authors:  T Iwatsubo; H Yamaguchi; M Fujimuro; H Yokosawa; Y Ihara; J Q Trojanowski; V M Lee
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

9.  Distribution of phosphoneuroprotein 14 (PNP 14) in vertebrates: its levels as determined by enzyme immunoassay.

Authors:  S Nakajo; K Tsukada; H Kameyama; Y Furuyama; K Nakaya
Journal:  Brain Res       Date:  1996-11-25       Impact factor: 3.252

10.  NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.

Authors:  M Yoshimoto; A Iwai; D Kang; D A Otero; Y Xia; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

View more
  494 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.

Authors:  L C Serpell; J Berriman; R Jakes; M Goedert; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 3.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

4.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 6.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

7.  Neuropathology in mice expressing human alpha-synuclein.

Authors:  H van der Putten; K H Wiederhold; A Probst; S Barbieri; C Mistl; S Danner; S Kauffmann; K Hofele; W P Spooren; M A Ruegg; S Lin; P Caroni; B Sommer; M Tolnay; G Bilbe
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

8.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

9.  The effect of truncation on prion-like properties of α-synuclein.

Authors:  Makoto Terada; Genjiro Suzuki; Takashi Nonaka; Fuyuki Kametani; Akira Tamaoka; Masato Hasegawa
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

Review 10.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.